EE25 Economic Benefit of Faricimab Compared to Aflibercept 8mg in Treating Patients with Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.326
https://www.valueinhealthjournal.com/article/S1098-3015(24)00441-8/fulltext
Title :
EE25 Economic Benefit of Faricimab Compared to Aflibercept 8mg in Treating Patients with Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00441-8&doi=10.1016/j.jval.2024.03.326
First page :
Section Title :
Open access? :
No
Section Order :
11673